We have a high aspiration: to save lives. As a Single Pill Company, we wish to achieve a paradigm shift with our innovative corporate performance and a reorientation in the long-term therapy of chronically-ill patients with cardiovascular diseases. By substituting loose combinations with the same active ingredient-containing Single Pill, we strive to increase the efficiency of the long-term therapy for chronically-ill patients, in order to prevent cardiovascular events. Thanks to the reduced number of tablets, the significantly increased patient compliance to therapy holds considerable medical and economic potential for improved patient care.
To satisfy this demand, we are passionately driving our innovation contribution: the Single Pill therapy concept, the development and market launch of new single pills as a substitute for frequently-combined single substances. We do our best, every day, to fully exploit the potential of the Single Pill. In the process, we wish to anchor the superiority of this concept for improved patient care in the minds of physicians. We are working in a solution-oriented manner to ensure that not only the medical community but also funders recognize this progress. Single Pill is more than merely a convenience solution; Single Pill opens up a new horizon for therapy. The benefits speak for themselves: simplified administration, significantly better therapy compliance, increased treatment success, reduced overall costs, and greater sustainability make for a better life in which we can all participate. Every day. This all leads to a single, overriding goal for us: establishing the Single Pill as the gold standard. This will make the Single Pill the standard of care in the long-term treatment of chronically-ill cardiovascular patients. This way, a better therapeutic outcome can be achieved – in line with the state of medical progress.
Contents on this page
The lives of millions of people depend on it. That's why our vision puts us under an obligation to act in a patient-focused way. We want to accelerate this paradigm shift. In the interest of affected patients, we see it as our task to make Single Pill therapy the new gold standard. We want physicians to abandon previously learned therapy routines in favor of new findings that are derived from evidence-based medicine, and to support them in implementing the current, guideline-based therapy in daily practice. Within this context, we also make use of digital activities. As a Single Pill Company, we place maximum importance on the Single Pill therapy concept. We are putting all our efforts into making Single Pill therapy a reality as standard care. Simple, in many ways, better.
Our Mission
Our mission is to maximize the potential of active ingredients by simplifying therapy and substitution with Single Pill, so as to maximize the potential of active ingredients.
Our Mission
We are passionate about simplifying and improving chronic disease therapy. With Single Pill, we increase the effect of medical therapy, thereby serving the patient's well-being. Not only the payer, but also the solidarity community of the insured benefit from considerable savings. Single Pill, for more sustainability in the long-term therapy of chronically-ill cardiovascular patients. In everyone’s interest.
The Single Pill concept is patient-focused. It reduces the daily number of tablets to be taken and achieves significantly higher therapy compliance. Patients no longer forget, or even refuse, to take some tablets. This improves the medical prognosis, in addition to increasing patients’ life expectancy. Apart from this, the consistent implementation of the Single Pill therapy principle in daily life results in considerable economic added value and contributes to cost reductions in the healthcare system. The Single Pill is sustainable. It replaces several individually-manufactured and packaged drugs by one pill. Far fewer preparations need to be manufactured, packaged and transported. By developing a large number of Single Pills for the benefit of all stakeholders, we multiply the therapy principle’s benefit. This way, Single Pill therapy also contributes to ecological and economic sustainability.
We wish to achieve further progress and are engaged in healthcare research together with our partners in the healthcare sector. Based on the evidence of Single Pill therapy, we specifically help physicians to leave behind previously learned therapy habits in favor of new medical and scientific findings. After all, structured, targeted medication management only works if chronically-ill patients are identified and single substances are consistently substituted by using the Single Pill. Our competent and motivated sales force not only informs physicians about our various Single Pills and new study results on the Single Pill therapy concept, but also provides solution-oriented support in the organizational implementation of the study evidence in real practice.
This is our contribution to the paradigm shift in the drug treatment of chronically ill cardiovascular patients. Several off-patent active ingredients, which previously had to be taken separately, are now combined in a Single Pill. The paradigm shift is: better therapy results, thanks to simplification with Single Pill.
We are living up to our claim of saving lives. By substituting loose substances with Single Pill, we are maximizing both the potential of the active ingredients and the economic and ecological potential of the Single Pill therapy concept. This way, we promote better and, in addition, sustainable patient care, thereby making an important contribution to society, with which we simply achieve more.
The Single Pill concept is patient-focused. It reduces the daily number of tablets to be taken and achieves significantly higher therapy compliance. Patients no longer forget, or even refuse, to take some tablets. This improves the medical prognosis, in addition to increasing patients’ life expectancy. Apart from this, the consistent implementation of the Single Pill therapy principle in daily life results in considerable economic added value and contributes to cost reductions in the healthcare system. The Single Pill is sustainable. It replaces several individually-manufactured and packaged drugs by one pill. Far fewer preparations need to be manufactured, packaged and transported. By developing a large number of Single Pills for the benefit of all stakeholders, we multiply the therapy principle’s benefit. This way, Single Pill therapy also contributes to ecological and economic sustainability.
We wish to achieve further progress and are engaged in healthcare research together with our partners in the healthcare sector. Based on the evidence of Single Pill therapy, we specifically help physicians to leave behind previously learned therapy habits in favor of new medical and scientific findings. After all, structured, targeted medication management only works if chronically-ill patients are identified and single substances are consistently substituted by using the Single Pill. Our competent and motivated sales force not only informs physicians about our various Single Pills and new study results on the Single Pill therapy concept, but also provides solution-oriented support in the organizational implementation of the study evidence in real practice.
This is our contribution to the paradigm shift in the drug treatment of chronically ill cardiovascular patients. Several off-patent active ingredients, which previously had to be taken separately, are now combined in a Single Pill. The paradigm shift is: better therapy results, thanks to simplification with Single Pill.
We are living up to our claim of saving lives. By substituting loose substances with Single Pill, we are maximizing both the potential of the active ingredients and the economic and ecological potential of the Single Pill therapy concept. This way, we promote better and, in addition, sustainable patient care, thereby making an important contribution to society, with which we simply achieve more.
Our Offer
We develop and market prognosis-improving drugs for chronically-ill patients.
Our Offer
The special feature of our product range is the combination of two to three off-patent active ingredients in a single dosage form. This replaces therapy with several individual preparations of the same substance and dose. Our focus is on cardiovascular diseases.
Our Single Pill portfolio already provides a solution for many cardiovascular patients who are currently still being treated with single substances. This increases patients’ life expectancy. The adherence rate for conventional medication is between 20 and 50 percent. Using the Single Pill, increases this significantly to 70-80 percent. The mortality rate is reduced by up to 49 percent. For many loose combinations, there is still no offer of a substance- and dose-matched Single Pill. We continue working at full speed to determine the further need for Single Pills and to constantly expand our range.
The Single Pill is a so-called “game changer” that will fundamentally change drug therapy. It is an offer for medical, economic and ecological progress in which the whole of society can participate. That is where we see our advantage. We simply offer more.
Our Single Pill portfolio already provides a solution for many cardiovascular patients who are currently still being treated with single substances. This increases patients’ life expectancy. The adherence rate for conventional medication is between 20 and 50 percent. Using the Single Pill, increases this significantly to 70-80 percent. The mortality rate is reduced by up to 49 percent. For many loose combinations, there is still no offer of a substance- and dose-matched Single Pill. We continue working at full speed to determine the further need for Single Pills and to constantly expand our range.
The Single Pill is a so-called “game changer” that will fundamentally change drug therapy. It is an offer for medical, economic and ecological progress in which the whole of society can participate. That is where we see our advantage. We simply offer more.
APONTIS PHARMA is the leading provider of single pill combinations in the cardiovascular field in the German healthcare market. By using single pill combinations, doctors can sustainably improve the prognosis of their patients with chronic diseases such as coronary heart disease. Since 2023, the National Health Care Guidelines have therefore given preference to single pill combinations over loose combinations of individual active ingredients.
At APONTIS PHARMA, we have made it our task to make guideline-compliant treatment with Single Pills available to as many patients as possible. We do this by providing targeted advice to treating physicians and a portfolio that covers all important loose combinations of active ingredients in a Single Pill. A Single Pill is a combination of two to three off-patent active ingredients with different dosages that is taken once a day.
At APONTIS PHARMA, we have made it our task to make guideline-compliant treatment with Single Pills available to as many patients as possible. We do this by providing targeted advice to treating physicians and a portfolio that covers all important loose combinations of active ingredients in a Single Pill. A Single Pill is a combination of two to three off-patent active ingredients with different dosages that is taken once a day.
Bruno Wohlschlegel
Chairman of the board